As the Democratic Republic of Congo deals with a rising death toll owing to the latest outbreak of Ebola, health officials are moving fast to counter the fatal effects of the deadly virus. Plans are afoot to implement the experimental vaccine developed by Merck & Co to confront the overwhelming challenges posed by the virus.
Developing specialty vaccines for emerging and overlooked infectious diseases is a challenging and rewarding enterprise with specific opportunities and problems. Large companies have not historically prioritized this area and instead have focused on the development and commercialization of routine vaccines and vaccines for diseases with more significant global markets.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.